Abstract
Complex abdominal wall hernias present significant surgical challenges due to high morbidity and recurrence rates. This study evaluates the efficacy of preoperative Botulinum Toxin Type A (BTA) injections as a "chemical component separation" technique to facilitate primary fascial closure by elongating the lateral abdominal muscles and increasing abdominal cavity volume.
Introduction
Repairing massive abdominal wall hernias often involves overcoming "lateral retraction," where muscles stiffen and pull away from the midline over time. In severe cases of "loss of domain," the abdominal cavity becomes physically too small to house the herniated organs. While traditional surgical component separation can provide the necessary slack, it is highly invasive. This research explores BTA as a preoperative "neoadjuvant" tool to non-invasively relax and stretch the abdominal wall before the patient enters the operating room.
Methods
This retrospective study analyzed 11 patients treated at Prince Sultan Military Medical City in Riyadh, Saudi Arabia, between 2021 and 2023. All participants presented with complex hernias, defined by transverse defects greater than 100 mm or significant loss of domain.
The clinical protocol involved:
- Baseline Imaging: CT scans were used to measure the initial hernia defect size and lateral muscle length.
- BTA Injection: Under ultrasound guidance, Botulinum Toxin Type A was injected into the three layers of the lateral abdominal wall (external oblique, internal oblique, and transversus abdominis).
- Waiting Period: A several-week interval allowed the toxin to block acetylcholine release, effectively paralyzing and thinning the muscles to facilitate stretching.
- Post-BTA Assessment: A second CT scan measured anatomical changes prior to surgical reconstruction.
Key Results
The quantitative findings support BTA as a highly effective surgical adjunct:
- Muscle Elongation: The most significant anatomical change was the increase in mean muscle length, which grew from 33.91 cm to 39.29 cm (p = 0.001).
- Defect Reduction: The average fascial gap decreased from 13.14 cm to 11.84 cm. While the p-value (0.094) was slightly above the standard threshold, the clinical impact on ease of closure was notable.
- Surgical Success: Primary fascial closure was successfully achieved in 10 out of 11 participants (90.9%).
- Safety and Follow-up: No significant adverse effects were reported. Over an average follow-up of 18.3 months, there were zero reported hernia recurrences.
Discussion and Conclusion
Preoperative BTA injection acts as a "chemical" version of surgical release. By temporarily paralyzing the lateral muscles, intra-abdominal pressure naturally stretches the fibers, increasing the volume of the abdominal cavity. This allows herniated organs to be safely returned to the abdomen without causing dangerous spikes in internal pressure or excessive tension on the surgical site.
While the study is limited by its small sample size and retrospective nature, the results suggest that BTA is a safe and powerful tool for transforming "impossible" hernia closures into manageable procedures. The authors call for larger, prospective multi-center trials to definitively validate BTA's role in the standard of care for complex abdominal wall reconstruction.
Summary updated